Effects of Liraglutide on Left Ventricular Function: A Meta-Analysis of Randomized, Placebo-Controlled Trials

Abstract

Background. The effects of liraglutide treatment on the left ventricular systolic and diastolic function remain unclear. Methods. This meta-analysis was conducted according to the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement. All relevant randomized, placebo-controlled trials (RCTs) were identified by searching PubMed, EMBASE, Cochrane Library, and ISI Web of Science from the establishment to January 2021 without language limitations. The weighted mean difference (WMD) with 95% confidence intervals (CIs) was calculated. Results. Ten placebo-controlled RCTs involving a total of 732 cases were included in the meta-analysis. Compared with the placebo group, liraglutide therapy showed no beneficial effect on the left ventricular ejection fraction (LVEF) at the end of the study (WMD: 2.120, 95% CI: −0.688 to 4.929, P = 0.139 ) and ΔLVEF during the trial period (WMD: −0.651, 95% CI: −1.649 to 0.348, P = 0. 202 ). Similarly, no statistical differences were noted in diastolic function parameters between the two groups, including the value early diastolic filling velocity (E)/the mitral annular early diastolic velocity ( e ′ ) (WMD: −0.763, 95% CI: −2.157 to 0.630, P = 0. 283 ), Δ e ′ (WMD: −0.069, 95% CI: −0.481 to 0.343, P = 0. 742 ), and Δ E / e ′ (WMD: −0.683, 95% CI: −1.663 to 0.298, P = 0. 172 ). Conclusions. Liraglutide treatment did not improve the left ventricular systolic and diastolic function. Given the study’s limitations, further investigation may be warranted.

A meta-analysis evaluating indirectly GLP-1 receptor agonists and arrhythmias in patients with type 2 diabetes and myocardial infarction

“…Thus, these mechanisms may be ineffective clinically. The research of Zhong et al may confirm our conjecture ( 32 ). Post-MI LV remodeling, a pathological change including cardiac structure and function, is closely associated with developing ventricular arrhythmias after MI ( 33 , 34 ).…”

“…It’s been proven that Liraglutide improved cardiac structure parameters such as left ventricular end-diastolic diameter (LVEDD) and left ventricular posterior wall thickness (LVPWT) ( 35 ). In the study of Zhong et al, though, Liraglutide did not improve the left ventricular ejection fraction (LVEF), the early filling velocity on transmittal Doppler/early relaxation velocity on tissue Doppler (E/e’) and other parameters of left ventricular systolic or diastolic function ( 32 ). Consequently, the effects of GLP-1RAs on LV remodeling might be moderate overall, and therefore its anti-ventricular arrhythmias potential is negligible.…”

“…This indicates that the above favorable mechanisms of GLP-1RAs on ventricular arrhythmias might be negligible or slight overall for humans, or might be diminished by other reasons. (32). Consequently, the effects of GLP-1RAs on LV remodeling might be moderate overall, and therefore its anti-ventricular arrhythmias potential is negligible.…”